| Robin D Ozerkis, A,R,N,O, | |
|
310 15th Ave E, Seattle, WA 98112-5103 | |
| (206) 326-3573 | |
| (206) 326-4532 |
| Full Name | Robin D Ozerkis |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 310 15th Ave E, Seattle, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588717953 | NPI | - | NPPES |
| 9613084 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | RN00101471 (Washington) | Secondary |
| 363L00000X | Nurse Practitioner | AP30002135 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robin D Ozerkis, A,R,N,O, Po Box 34581, Seattle, WA 98124-1581 Ph: (509) 241-7349 | Robin D Ozerkis, A,R,N,O, 310 15th Ave E, Seattle, WA 98112-5103 Ph: (206) 326-3573 |
News Archive
Northborough, MA-based Bertucci's Corporation announced today that it's own Chef Stefano Cordova has been chosen by First Lady Michelle Obama to participate in her "Chefs Move To Schools" program that calls on the nation's chefs to adopt a school, work with teachers, parents, school nutritionists and administrators to help educate kids about food and nutrition.
Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board ("DSMB") has reviewed the safety data from the first group of patients enrolled in its pivotal ThermoDox® Phase III clinical trial for primary liver cancer ("HEAT study") and has recommended that Celsion continue to enroll patients in the trial.
In a recent discovery by University of Minnesota Medical School, researchers uncovered a new way to potentially target and treat late-stage colorectal cancer - a disease that kills more than 50,000 people each year in the United States.
GenSpera, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to begin a Phase I study with its target activated pro-drug, G-202, for the treatment of cancer.
Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.
› Verified 5 days ago
Mrs. Joanne Lynn Osetsky, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 550 17th Ave, Ste 110, Seattle, WA 98122 Phone: 206-320-3470 Fax: 206-320-3471 | |
Sandra K Walker, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-598-0502 Fax: 206-598-0516 | |
Ms. Jennifer Patano, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4800 Sand Point Way Ne, Ms O.7.720, Seattle, WA 98105 Phone: 206-987-8949 Fax: 206-987-8943 | |
Mrs. Dominique Michelle Well, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 4715 42nd Ave Sw, Seattle, WA 98116 Phone: 206-265-3642 | |
Mrs. Susan L Holtzclaw, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4800 Sand Point Way Ne, Mailstop T-2108, Seattle, WA 98105 Phone: 206-987-5691 | |
Dr. Kaitlin Michelle Brasier, D.N.P., A.R.N.P., RN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1525 4th Ave, Suite 300, Seattle, WA 98101 Phone: 206-838-6856 Fax: 206-838-3085 | |
Melissa Yen-ching Lo, DNP, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-861-3396 |